DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema

Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Uveitis; Cystoid Macular Edema

Intervention: Diclophenac (Drug); Triamcinolone (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Shahid Beheshti Medical University


Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In some patients, CME persists even after inflammation control, and additional treatment is needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the principles in treatment, but some complications like cataracts and increased ocular pressure have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug in all curative centers it could be applied instead of Triamcinolone.

Clinical Details

Official title: The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- cystoids macular edema which is diagnosed by OCT and flurocein angiography

- 5/200 < Visual acuity < 20/50

- resistance to routine treatment (oral treatment, periocular injection)

Exclusion Criteria:

- history of retinal disease cause macular edema like diabetes

- arterial occlusion

- monocular patients

- patients candidate for intra-ocular operation

- history of glaucoma or ocular hypertension

- any cataract that would interfere with OCT

Locations and Contacts

Ophthalmic Research Center, Tehran 166666, Iran, Islamic Republic of; Recruiting
Masoud Soheilian, MD, Phone: +98 21 22585952, Email: labbafi@hotmail.com
Additional Information

Last updated: May 4, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017